Alert detail
LCD L36089: MolDX: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Palmetto GBA
What changed
MolDX LCD defines covered thrombophilia genetic testing criteria in 7 SE states.
Who’s affected: Clinical Laboratory billing teams · Effective: July 20, 2023
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 8 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.